PMID- 27319780
OWN - NLM
STAT- MEDLINE
DCOM- 20180822
LR  - 20190420
IS  - 2041-1723 (Electronic)
IS  - 2041-1723 (Linking)
VI  - 7
DP  - 2016 Jun 20
TI  - Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy.
PG  - 11838
LID - 10.1038/ncomms11838 [doi]
LID - 11838
AB  - The application of nanoparticle drug formulations, such as nanoliposomal 
      doxorubicin (Doxil), is increasingly integrated in clinical cancer care. Despite 
      nanomedicine's remarkable potential and growth over the last three decades, its 
      clinical benefits for cancer patients vary. Here we report a non-invasive 
      quantitative positron emission tomography (PET) nanoreporter technology that is 
      predictive of therapeutic outcome in individual subjects. In a breast cancer 
      mouse model, we demonstrate that co-injecting Doxil and a Zirconium-89 
      nanoreporter ((89)Zr-NRep) allows precise doxorubicin (DOX) quantification. 
      Importantly, (89)Zr-NRep uptake also correlates with other types of 
      nanoparticles' tumour accumulation. (89)Zr-NRep PET imaging reveals remarkable 
      accumulation heterogeneity independent of tumour size. We subsequently 
      demonstrate that mice with >25 mg kg(-1) DOX accumulation in tumours had 
      significantly better growth inhibition and enhanced survival. This non-invasive 
      imaging tool may be developed into a robust inclusion criterion for patients 
      amenable to nanotherapy.
FAU - Perez-Medina, Carlos
AU  - Perez-Medina C
AD  - Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount 
      Sinai, New York, New York 10029, USA.
AD  - Centro de Investigacion en Red de Enfermedades Respiratorias, 28029 Madrid, 
      Spain.
AD  - Advanced Imaging Unit, Centro Nacional de Investigaciones Cardiovasculares, CNIC, 
      28029 Madrid, Spain.
FAU - Abdel-Atti, Dalya
AU  - Abdel-Atti D
AD  - Memorial Sloan Kettering Cancer Center, Department of Radiology, New York, New 
      York 10065, USA.
FAU - Tang, Jun
AU  - Tang J
AD  - Memorial Sloan Kettering Cancer Center, Department of Radiology, New York, New 
      York 10065, USA.
FAU - Zhao, Yiming
AU  - Zhao Y
AD  - Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount 
      Sinai, New York, New York 10029, USA.
FAU - Fayad, Zahi A
AU  - Fayad ZA
AD  - Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount 
      Sinai, New York, New York 10029, USA.
FAU - Lewis, Jason S
AU  - Lewis JS
AD  - Memorial Sloan Kettering Cancer Center, Department of Radiology, New York, New 
      York 10065, USA.
AD  - Department of Radiology, Weill Cornell Medical College, New York, New York 10065, 
      USA.
AD  - Molecular Pharmacology &Chemistry Program, Memorial Sloan Kettering Cancer 
      Center, New York, New York 10065, USA.
FAU - Mulder, Willem J M
AU  - Mulder WJM
AD  - Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount 
      Sinai, New York, New York 10029, USA.
AD  - Department of Medical Biochemistry, Academic Medical Center, 1105 AZ Amsterdam, 
      The Netherlands.
FAU - Reiner, Thomas
AU  - Reiner T
AD  - Memorial Sloan Kettering Cancer Center, Department of Radiology, New York, New 
      York 10065, USA.
AD  - Department of Radiology, Weill Cornell Medical College, New York, New York 10065, 
      USA.
LA  - eng
GR  - R01 HL125703/HL/NHLBI NIH HHS/United States
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - R01 CA155432/CA/NCI NIH HHS/United States
GR  - K25 EB016673/EB/NIBIB NIH HHS/United States
GR  - R01 EB009638/EB/NIBIB NIH HHS/United States
GR  - R01 HL118440/HL/NHLBI NIH HHS/United States
GR  - R01 CA172546/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20160620
PL  - England
TA  - Nat Commun
JT  - Nature communications
JID - 101528555
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 0 (Radiopharmaceuticals)
RN  - 0 (liposomal doxorubicin)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 80168379AG (Doxorubicin)
RN  - C6V6S92N3C (Zirconium)
SB  - IM
MH  - Animals
MH  - Antibiotics, Antineoplastic/pharmacokinetics/*pharmacology
MH  - Biological Transport
MH  - Doxorubicin/*analogs & derivatives/pharmacokinetics/pharmacology
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Mammary Neoplasms, Experimental/*diagnostic imaging/mortality/pathology/therapy
MH  - Mice
MH  - Nanoparticles/administration & dosage/chemistry
MH  - Polyethylene Glycols/pharmacokinetics/pharmacology
MH  - Positron-Emission Tomography/*methods
MH  - Radiopharmaceuticals/administration & dosage
MH  - Survival Analysis
MH  - Theranostic Nanomedicine/*methods
MH  - Tissue Distribution
MH  - Zirconium/*administration & dosage
PMC - PMC4915130
EDAT- 2016/06/21 06:00
MHDA- 2018/08/23 06:00
PMCR- 2016/06/20
CRDT- 2016/06/21 06:00
PHST- 2015/10/21 00:00 [received]
PHST- 2016/05/05 00:00 [accepted]
PHST- 2016/06/21 06:00 [entrez]
PHST- 2016/06/21 06:00 [pubmed]
PHST- 2018/08/23 06:00 [medline]
PHST- 2016/06/20 00:00 [pmc-release]
AID - ncomms11838 [pii]
AID - 10.1038/ncomms11838 [doi]
PST - epublish
SO  - Nat Commun. 2016 Jun 20;7:11838. doi: 10.1038/ncomms11838.